{"id":"NCT00295620","sponsor":"AstraZeneca","briefTitle":"Secondary Adjuvant Long Term Study With Arimidex","officialTitle":"A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-03-01","primaryCompletion":"2017-06-30","completion":"2017-06-30","firstPosted":"2006-02-24","resultsPosted":"2019-10-02","lastUpdate":"2019-10-02"},"enrollment":3484,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Anastrozole","otherNames":["Arimidex"]}],"arms":[{"label":"Arm A: Anastrozol","type":"EXPERIMENTAL"},{"label":"Arm B: Anastrozol","type":"EXPERIMENTAL"}],"summary":"The study assesses the effect of further 2 years vs further 5 years of adjuvant treatment with anastrozole after initial 5 years of adjuvant endocrine therapy.","primaryOutcome":{"measure":"Disease-free Survival After Prolonged Endocrine Treatment","timeFrame":"DFS was defined as the time from two years after randomization to the earliest occurrence of loco-regional recurrence, distant recurrence, contralateral new breast cancer, second cancer or death from any cause, assessed up to a maximum of 8.5 years","effectByArm":[{"arm":"Arm A: Anastrozol","deltaMin":null,"sd":null},{"arm":"Arm B: Anastrozol","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.425"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":60,"countries":["Austria"]},"refs":{"pmids":["34320285"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2464&filename=1033AU0003_CSP_redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2464&filename=1033AU0003_SAP_redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":687,"n":1710},"commonTop":[]}}